Artwork
iconShare
 
Manage episode 435841126 series 3381831
Content provided by MPR Weekly Dose. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MPR Weekly Dose or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.

  continue reading

250 episodes